Adaptive Biotechnologies Valuation

Is 1HM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1HM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 1HM's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 1HM's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1HM?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 1HM. This is calculated by dividing 1HM's market cap by their current preferred multiple.
What is 1HM's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	US$722.61m

1HM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.9x
Enterprise Value/EBITDA	-4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 1HM's PS Ratio compare to its peers?

The above table shows the PS ratio for 1HM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3.3x
EVT Evotec	1.4x	11.4%	€1.1b
GXI Gerresheimer	1.7x	10.9%	€3.4b
1SXP SCHOTT Pharma KGaA	4.9x	10.7%	€4.7b
SRT3 Sartorius	5.2x	9.2%	€15.8b
1HM Adaptive Biotechnologies	4.4x	18.8%	€722.6m

Price-To-Sales vs Peers: 1HM is expensive based on its Price-To-Sales Ratio (4.4x) compared to the peer average (3.3x).

Price to Earnings Ratio vs Industry

How does 1HM's PE Ratio compare vs other companies in the European Life Sciences Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	25.9%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	25.9%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: 1HM is good value based on its Price-To-Sales Ratio (4.4x) compared to the European Life Sciences industry average (5x).

Price to Sales Ratio vs Fair Ratio

What is 1HM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1HM PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	4.4x
Fair PS Ratio	1.8x

Price-To-Sales vs Fair Ratio: 1HM is expensive based on its Price-To-Sales Ratio (4.4x) compared to the estimated Fair Price-To-Sales Ratio (1.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1HM forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	€4.22	€6.11 +44.8%	23.0%	€8.95	€4.47	n/a	6
Sep ’25	€4.16	€6.24 +50.0%	23.0%	€9.13	€4.56	n/a	6
Aug ’25	€4.15	€5.89 +41.9%	28.3%	€9.31	€4.65	n/a	6
Jul ’25	€3.35	€5.89 +75.8%	28.3%	€9.31	€4.65	n/a	6
Jun ’25	€3.03	€5.89 +94.7%	28.3%	€9.31	€4.65	n/a	6
May ’25	€2.53	€6.15 +143.2%	28.3%	€9.23	€4.61	n/a	6
Apr ’25	€2.99	€6.34 +112.0%	25.9%	€9.28	€4.64	n/a	6
Mar ’25	€3.75	€6.34 +68.9%	25.9%	€9.28	€4.64	n/a	6
Feb ’25	€3.35	€7.92 +136.5%	23.7%	€10.05	€5.48	n/a	6
Jan ’25	€4.77	€8.45 +77.4%	21.3%	€10.14	€5.53	n/a	6
Dec ’24	€3.96	€8.45 +113.5%	21.3%	€10.14	€5.53	n/a	6
Nov ’24	€4.28	€11.06 +158.5%	15.6%	€14.16	€8.50	n/a	7
Oct ’24	€5.18	€11.77 +127.3%	11.1%	€14.04	€10.29	n/a	7
Sep ’24	€6.16	€10.79 +75.1%	19.0%	€13.63	€6.36	€4.16	8
Aug ’24	€7.43	€11.45 +54.2%	20.6%	€13.61	€6.35	€4.15	8
Jul ’24	€6.18	€11.45 +85.4%	20.6%	€13.61	€6.35	€3.35	8
Jun ’24	€6.42	€11.45 +78.5%	20.6%	€13.61	€6.35	€3.03	8
May ’24	€6.33	€11.91 +88.0%	20.6%	€14.15	€6.60	€2.53	8
Apr ’24	€7.61	€11.91 +56.5%	20.6%	€14.15	€6.60	€2.99	8
Mar ’24	€7.95	€11.91 +49.8%	20.6%	€14.15	€6.60	€3.75	8
Feb ’24	€8.38	€12.26 +46.2%	25.5%	€16.97	€6.60	€3.35	8
Jan ’24	€6.98	€12.25 +75.4%	25.3%	€16.96	€6.59	€4.77	7
Dec ’23	€8.12	€12.04 +48.3%	31.2%	€17.96	€6.98	€3.96	7
Nov ’23	€7.79	€13.26 +70.3%	34.9%	€21.07	€7.52	€4.28	7
Oct ’23	€7.60	€14.32 +88.6%	29.4%	€21.06	€8.02	€5.18	7
Sep ’23	€8.74	€14.32 +63.9%	29.4%	€21.06	€8.02	€6.16	7

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.